Hoba Therapeutics
- Company typePrivate
- Founded2016
- HeadquartersCopenhagen, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Hoba Therapeutics firmographics
Firmographics- Name
- Hoba Therapeutics
- Legal name
- Hoba Therapeutics ApS
- Website
- https://hobatherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Hoba Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology) (HLAIALAC)
Keywords
Where Hoba Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Hoba Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development & Licensing: Pre-revenue biotech company. Revenue expected to come from licensing deals, co-development partnerships, and eventual product commercialization upon regulatory approval. The company is developing two therapeutic protein candidates (HB-086 for neuropathic pain, HB-097 for hearing loss) through preclinical and clinical development stages.
Go-to-market motion1 record
Marketing channels4 records
Hoba Therapeutics product offering
Product offeringCore offering
Hoba Therapeutics develops proprietary therapeutic protein drug candidates based on the endogenous human neurotrophic factors meteorin and cometin. Its lead candidate HB-086 (recombinant human meteorin) is in late preclinical development for chronic neuropathic pain, with target indications including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. The second candidate HB-097 (recombinant human cometin) is in preclinical development for sensorineural hearing loss, with ototoxic hearing loss as the target indication.
Product overview
Hoba Therapeutics is an early-stage Danish biotech developing two novel biopharmaceutical drugs based on proprietary neurotrophic factors (meteorin and cometin). The core portfolio consists of HB-086, a recombinant human meteorin for chronic neuropathic pain conditions (CIPN, trigeminal neuralgia), and HB-097, a recombinant human cometin for sensorineural hearing loss. Both are therapeutic proteins and the only members of a recently discovered family of neurotrophic factors with unique actions on sensory nerve cells and surrounding support cells.
Differentiator
Problem solved
Functional benefit
Products and services
- HB-086 (Meteorin) HB-086 is a recombinant human meteorin therapeutic protein in late preclinical development for chronic neuropathic pain. It is a non-opioid treatment targeting the peripheral nervous system, intended to reverse neuropathic pain and address the underlying cause of disease rather than masking symptoms. Target indications include Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. Preclinical data show robust, long-lasting analgesic effect up to three weeks.
- HB-097 (Cometin) HB-097 is a recombinant human cometin therapeutic protein in preclinical development for sensorineural hearing loss. Preclinical data show both preventive effects (by protecting nerve cells) and regenerative effects (by reversing already induced damage). Target indication is ototoxic hearing loss, with potential also for age-related and noise-induced hearing loss.
Quantifiable outcome
- Sustained analgesic effect lasting up to 3 weeks in preclinical studies
- +2 more outcomes
Companies that use Hoba Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Hoba Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Hoba Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered supporting.
- Columbia University (Dept. Neurology)supportingPart of consortium receiving DKK 18.4M funding. Multidisciplinary team led by Professor M. Hirano studying neuropathic pain caused by chemotherapy, including basic researchers, clinical neurologists and oncologists.
- University of Copenhagen (NNCPR)supportingPart of consortium. Novo Nordisk Fund's Center for Protein Research, led by Prof. Jesper V. Olsen, provides proteomics expertise for dynamic protein-protein interactions and protein expression profiling.
- Aarhus University (Department of Biomedicine)supportingPart of consortium. Christian B. Vægter's group internationally recognized for research of peripheral neuropathies and role of glial cells in nervous system.
- Selexis SAsupportingGlobal leader in cell line development providing best-in-class modular technology and specialized solutions enabling rapid discovery, development and commercialization of innovative medicines and vaccines.
- AxxamsupportingInnovative Partner Research Organization (iPRO) providing science-driven discovery services to life sciences companies in pharma, biotech, animal health, agrochemical and nutrition sectors.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Hoba Therapeutics competitors and assessment
Company assessmentDirect peers
- Pipeline Therapeutics: Clinical-stage biotech developing regenerative small molecules and biologics for hearing loss and neurotology; directly comparable to Hoba's HB-097 in regenerative approach to sensorineural hearing loss.
- Eliem Therapeutics: Clinical-stage biotech focused on CNS indications including neuropathic pain and epilepsy; comparable in therapeutic-area focus, development stage and small-cap biotech profile to Hoba.
- Aptinyx: Clinical-stage biotech developing NMDA-receptor modulators (e.g., NYX-2925) for chronic neuropathic pain; directly comparable in indication and development-stage biotech profile to Hoba's HB-086 program.
- Helixmith: Clinical-stage biotech developing enginerin (a neurotrophic factor biologic) for diabetic peripheral neuropathy and other neuropathic conditions; the closest mechanistic analogue to Hoba's HB-086 meteorin program.
- Frequency Therapeutics: Clinical-stage biotech developing regenerative therapeutics for sensorineural hearing loss; directly comparable to Hoba's HB-097 program in modality (regenerative biologic) and indication.
- Otonomy: Clinical-stage biotech developing therapeutics for ear disorders including sensorineural hearing loss; comparable to HB-097 in indication and small-cap biotech profile.
Emerging players
- Navega Therapeutics: Preclinical/early-clinical biotech developing gene therapy-based approaches to chronic neuropathic pain; an emerging player using a different modality but addressing the same unmet need as HB-086.
- Latigo Biotherapeutics: Biotech developing non-opioid Nav1.7-targeted therapeutics for pain; overlaps with Hoba's mission of replacing opioids in chronic pain and represents an emerging competitive modality in the same indication.
- Acousia Therapeutics: European biotech developing small-molecule therapeutics for sensorineural hearing loss; an emerging regional peer with overlapping indication to HB-097.
Broad incumbents
- Vertex Pharmaceuticals: Large commercial-stage biopharma developing non-opioid pain therapies (e.g., VX-548/Journavx for acute pain and follow-on NaV1.8 programs); serves as the broad incumbent setting the competitive bar in non-opioid pain where Hoba's HB-086 also competes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Hoba Therapeutics social profiles
Digital presenceHoba Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hoba Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Hoba Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hoba Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hoba Therapeutics
What does Hoba Therapeutics do?
Hoba Therapeutics develops proprietary therapeutic protein drug candidates based on the endogenous human neurotrophic factors meteorin and cometin. Its lead candidate HB-086 (recombinant human meteorin) is in late preclinical development for chronic neuropathic pain, with target indications including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. The second candidate HB-097 (recombinant human cometin) is in preclinical development for sensorineural hearing loss, with ototoxic hearing loss as the target indication.
Is Hoba Therapeutics a public or private company?
Hoba Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hoba Therapeutics founded?
Hoba Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Hoba Therapeutics based?
Hoba Therapeutics is headquartered in Copenhagen, Denmark, in the Europe region.
How does Hoba Therapeutics make money?
One revenue line is on record: drug Development & Licensing.
Who are Hoba Therapeutics's main competitors?
Direct peers on record are Pipeline Therapeutics, Eliem Therapeutics, Aptinyx, Helixmith, Frequency Therapeutics and Otonomy. Emerging players are Navega Therapeutics, Latigo Biotherapeutics and Acousia Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent.
Does Hoba Therapeutics have an API?
No public API is recorded for Hoba Therapeutics.
What industry is Hoba Therapeutics in?
Hoba Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 5417.